Drawing on the Anticalins' simple, stable and utilitarian structure, Pieris' proprietary Anticalin technology moves beyond current targeted therapeutic approaches, creating an astounding breadth of application. This, in addition to an inherently positive safety profile and a proven ability to deliver coveted affinity and specificity, promises to create safe drugs with improved efficacy and convenient routes of administration.
Anticalins are destined:
- to improve efficacy by specifically binding targets previously considered too small for other targeted approaches;
- to avoid unwanted agonistic receptor cross-linking activity due to their monovalent, monomeric nature;
- to expand treatment modalities by enabling inhaled and time-released "depot" formulations, among other novel delivery forms;
- to provide simplified bi-specific (Duocalin®) approaches, with single-gene expression;
- to rapidly advance from discovery through development to market with comparably lower cost of goods, relying on optimized discovery techniques and quality bacterial expression technologies; and
- to avoid safety issues based on their endogenous human protein progenitors that naturally bind and transport ligands.